Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pivampicillin is a semisynthetic, orally active pivaloyloxymethyl ester of ampicillin and serves as a prodrug to enhance the oral bioavailability of ampicillin due to its increased lipophilicity. After oral administration, it is rapidly hydrolyzed by non-specific esterases in the body to release active ampicillin along with formaldehyde and pivalic acid. Ampicillin exerts its antibacterial effect by binding to and inactivating penicillin-binding proteins (PBPs) on the bacterial cell wall's inner membrane. This action inhibits peptidoglycan cross-linking necessary for cell wall strength and rigidity, leading to bacterial cell lysis. Pivampicillin is primarily indicated for treating susceptible bacterial infections such as gonococcal urethritis and other infections responsive to ampicillin[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pivampicillin.